Shots:

• The two companies collaborated to evaluate the safety- tolerability- and preliminary efficacy of UbiVac’s DPV-00 in combination with BMS’ anti-OX40 (BMS-986178) combined with Opdivo (nivolumab)
• The P-Ib study will test the hypothesis that combination immunotherapy with the DPV-001 vaccine and anti-OX40 will boost anticancer immunity in patients with advanced TNBC
• UbiVac’s DRibble Platform Vaccine- DPV-001 contains 100+ proteins overexpressed by the average TNBC and as many as 1-700 altered peptide ligands that can enhance immunity against cancer antigens

Click here to read full press release/ article 

Ref: BusinessWire | Image: BMS